tradingkey.logo

Relmada Therapeutics Inc <RLMD.OQ> expected to post a loss of 31 cents a share - Earnings Preview

ReutersMay 9, 2025 10:29 PM
  • Relmada Therapeutics Inc RLMD.OQ RLMD.O is expected to show no change in quarterly revenue when it reports results on May 12 for the period ending March 31 2025

  • ​LSEG's mean analyst estimate for Relmada Therapeutics Inc is for a loss of 31 cents per share.

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell."

  • The mean earnings estimate of analysts was unchanged in the last three months. ​

  • Wall Street's median 12-month price target for Relmada Therapeutics Inc is $1.00​, above​ its last closing price of $0.42. ​​​

This summary was machine generated May 9 at 22:29 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI